{"entity":{"id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of REGN5093 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.","summary":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04077099 by Regeneron Pharmaceuticals, with 95 participants enrolled, started 2020-01-07 and due to reach its primary completion in 2027-07-06. Interventions recorded: REGN5093.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04077099","url":"https://clinicaltrials.gov/study/NCT04077099"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04077099","phase":"1/2","setting":"A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","sponsor":"Regeneron Pharmaceuticals","enrolled":95,"outcomes":[]},"route":"/trials/nct04077099/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}